Atherosclerosis is a disease in which atherosclerotic plaques form in the walls of the arteries of medium or large arteries, resulting in reduced blood flow or blocking the outflow of blood. Ace Therapeutics provides integrated basic research and drug development services to further explore the pathogenesis and novel therapeutic approaches to atherosclerosis.
Impaired lipid metabolism is the basis of atherosclerosis, which is characterized by the involvement of arterial lesions starting from the intima, generally preceded by accumulation of lipids and complex sugars, hemorrhage and thrombosis, and then fibrous tissue hyperplasia and calcium deposits, and gradual metamorphosis and calcification of the arterial mid-layer, leading to thickening and hardening of the arterial wall and narrowing of the vessel lumen. There is an increasing number of studies that have elucidated the pathogenesis of atherosclerosis from an epigenetic perspective, uncovering a large number of novel therapeutic targets and laying the foundation for the development of novel therapeutic approaches.
Fig. 1 Overview of inflammatory responses in atherosclerotic development. (Kong P, et al., 2022)
In recent years, pharmacological therapy strategies for atherosclerosis have focused on regulating lipid metabolism and lowering blood lipid levels. Currently, in the development of atherosclerosis drugs, many new types of drugs have received widespread attention and are considered to have the potential to be developed into new therapeutic drugs for atherosclerosis.
Overview of Novel Drugs for Atherosclerosis
| Drug Name | Drug Target | Original Organization | Drug Phase |
|---|---|---|---|
| Inclisiran | PCSK9 | Alnylam Pharmaceuticals, Inc. | Approved |
| Bempedoic acid | ACL | Esperion Therapeutics, Inc. | Approved |
| Doravirine | Reverse Transcriptase | Merck Co., Inc. | Approved |
| Semaglutide | GLP-1R | Novo Nordisk A/S | Approved |
| Beperminogene perplasmid | c-Met | AnGes, Inc. | Approved |
| Pelacarsen | lipoprotein(a) | Ionis Pharmaceuticals, Inc. | Phase 3 |
| Lepodisiran | lipoprotein(a) | Dicerna Pharmaceuticals, Inc. | Phase 2 |
Ace Therapeutics strives to provide outsourced research services in disease model development and related research technology platforms to support basic research and development of novel therapeutic approaches for atherosclerosis.
Research Models
Basic Research
Drug Development
In recent years, many types of atherosclerosis research models have been reported, which can be used in a wide range of atherosclerosis research fields. We are able to provide customized atherosclerosis research models to support our clients' research into the pathogenesis of atherosclerosis and the development of novel therapeutic agents.
Custom Animal Models of Atherosclerosis
We can offer development services for a variety of animal models of atherosclerotic diseases to meet the individual needs of our customers during their experimental research.
Transgenic Animal Model Development Services
Genetic factors play an important role in the development and progression of atherosclerosis. We can provide customized services for developing transgenic or knockout animal models, including but not limited to the following genes:
Genetically Engineered Mouse Models
We can provide the following high quality genetically engineered mice for atherosclerosis research.
Cardiomyocyte Cell Lines
For in vitro studies, we can provide our clients with a wide range of cardiomyocyte cell lines.
For basic research on atherosclerosis, we have a series of mature research technology platforms to help clients study the pathogenesis of coronary heart disease and evaluate the efficacy of pharmaceutical agents.
Pathogenesis Research Services
Many research has shown that genetic factors play a crucial role in the pathogenesis of atherosclerosis. We have a mature multi-omics research technology platform that can help our clients explore the disease mechanism of atherosclerosis at gene level, protein expression level and metabolite analysis.
Pathology and Imaging Services
For animal models of atherosclerosis, pathology and imaging studies can reflect the status of the animal model most intuitively. We can provide pathology and imaging services for animal experiments for animal model validation and drug efficacy evaluation.
Based on our specialized novel drug research technology platform, we can provide research outsourcing services for atherosclerosis drug development, including but not limited to the following drug types and targets:
R&D Services by Drug Type
R&D Services by Target
Ace Therapeutics has been deeply involved in cardiovascular disease research for many years, and has accumulated rich knowledge of coronary heart disease research. We can provide our customers with basic research and novel therapies discovery services. If you are interested in our services for atherosclerosis, please don't hesitate to contact us.
Ace Therapeutics offers comprehensive solutions and R&D services to researchers worldwide to advance the field of cardiovascular diseases.
We do not provide medical care for patients.
Copyright © Ace Therapeutics. All rights reserved.